Can Pulmonary Alveolar Proteinosis Present in Infancy?
Yes, pulmonary alveolar proteinosis (PAP) can definitely present in infancy, typically as congenital PAP caused by genetic mutations affecting surfactant production or metabolism, and it represents a critical cause of severe, difficult-to-treat respiratory failure in full-term neonates.
Clinical Presentation in Infants
PAP presenting in infancy manifests with distinct characteristics that differ from adult-onset disease:
- Timing: Respiratory distress begins immediately or within days to weeks after birth 1, 2
- Key symptoms: Progressive dyspnea, hypoxemia requiring supplemental oxygen, and inability to wean from oxygen support 1, 3
- Severity: Often presents as severe respiratory failure requiring intensive support 4, 2
Underlying Etiology in Infants
According to the 2024 ERS guidelines, PAP results from mechanistically distinct diseases 5. In infants specifically:
Congenital PAP is the predominant form, caused by mutations in genes encoding surfactant proteins or genes involved in surfactant production/lung development 5. The most commonly implicated gene is ABCA3, as demonstrated in a 2023 case of a 44-day-old infant with compound heterozygous ABCA3 mutations 1.
This differs fundamentally from adult PAP, where autoimmune PAP (driven by GM-CSF antibodies) predominates. Autoimmune PAP is exceedingly rare in young children, though it can occur in older pediatric patients 6.
Diagnostic Approach in Infants
When congenital PAP is suspected in an infant with persistent, difficult-to-treat dyspnea:
Chest CT scan: Look for the characteristic "crazy-paving" pattern (ground-glass opacities with interlobular septal thickening) 1
Bronchoalveolar lavage fluid (BALF) analysis: Demonstrates periodic acid-Schiff (PAS)-positive proteinaceous deposits 1, 2
Genetic testing: Essential for confirming congenital PAP and identifying specific mutations (ABCA3, SFTPB, SFTPC, etc.) 5, 1
Lung biopsy: May be necessary when less invasive methods are inconclusive, showing dense PAS-positive granular material within alveolar spaces 7, 2
Critical pitfall: Do not delay genetic testing while pursuing empiric treatment for presumed infection or other causes of neonatal respiratory distress 1.
Prognosis and Management Considerations
The prognosis for congenital PAP in infancy is generally poor:
- Multiple case reports document death within the first year of life despite treatment 7, 2
- Bronchoalveolar lavage (partial or whole lung lavage) can be performed even in young infants and may provide temporary clinical improvement 3, 4
- However, unlike autoimmune PAP in adults where whole lung lavage is highly effective, congenital forms often have progressive courses 5
Treatment approach: Partial lung lavage using flexible bronchoscopy can be performed in infants as young as 4-6 months using specialized techniques that allow selective ventilation of one lung while lavaging the contralateral lung 3, 4. In severe cases, extracorporeal support may be required 4.
Key Clinical Pearls
- Family history matters: A sibling death from early respiratory failure should immediately raise suspicion for congenital PAP 1
- Full-term infants: Congenital PAP typically affects full-term, not premature, infants—distinguishing it from surfactant deficiency of prematurity 1, 2
- Early recognition is critical: Despite poor prognosis, early diagnosis through CT, BALF, and genetic testing allows for appropriate counseling and potential therapeutic interventions 1